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ABSTRACT. 
 
We have investigated the expression and role of galectin-1 and other galectins 
in psoriasis and in the Th1/Th17 effector and dendritic cell responses 
associated with this chronic inflammatory skin condition. To determine 
differences between psoriasis patients and healthy donors, galectins expression 
was analyzed by RT-PCR assays in skin samples and specifically on epidermal 
and peripheral blood dendritic cells by immunofluorescence and flow cytometry. 
In skin of healthy donors galectins 1, 3 and 9 were expressed in a high 
proportion of Langerhans cells. Also, galectins were differentially expressed in 
peripheral blood dendritic cell subsets; galectin-1 and galectin-9 were highly 
expressed in peripheral myeloid dendritic cells compared with plasmacytoid 
dendritic cells. We found that non-lesional as well as lesional skin samples from 
psoriasis patients had low levels of galectin-1 at mRNA and protein level in 
parallel with low levels of IL-10 mRNA compared with skin from healthy 
patients. However, only lesional skin samples expressed high levels of 
Th1/Th17 cytokines. The analysis of galectin-1 expression on dendritic cells 
showed that this protein was downregulated in Langerhans cells as well as in 
peripheral blood CD11c+ DCs from psoriasis patients. Addition of galectin-1 to 
co-cultures of human monocyte-derived dendritic cells with autologous T 
lymphocytes from psoriasis patients attenuated the Th1 response. Conversely, 
blockade of galectin binding increased IFN-gamma production and inhibited IL-
10 secretion in co-cultures of monocyte-derived dendritic cells with CD4+ T 
cells. Our results suggest a model in which galectin-1 downregulation 
contributes to the exacerbation of the Th1/Th17 effector response in psoriasis 
patients.  
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INTRODUCTION. 
Galectins are a family of highly-conserved glycan-binding proteins. Although 
initially described as mediators of developmental processes, members of the 
galectin family are now known to play important roles in the innate and adaptive 
immune responses [1, 2]. 
Growing evidence indicates that galectin-1 (gal-1) functions as a 
negative regulator of the inflammatory response. In vitro studies revealed that 
gal-1 limits the immune response, for example promoting apoptosis of Th-1 
cells, inducing IL-10, or down-regulating pro-inflammatory cytokines [3, 4]. 
Exogenous gal-1 has immunosuppressive and anti-inflammatory effects in 
experimental models of inflammation and autoimmunity such as inflammatory 
bowel disease, autoimmune retinal disease, autoimmune diabetes, and 
collagen-induced arthritis [5-8]. In addition, gal-1-deficient mice show 
augmented Th1 and Th17 responses and enhanced susceptibility to 
autoimmune neuroinflammation [3]. 
Similarly to gal-1, gal-9 down-regulates Th-1 and Th17 responses, and is 
involved in the suppression induced by CD4+ CD25+ regulatory T cells through 
its interaction with the Th-1-specific cell surface molecule TIM-3 [9, 10]. Studies 
in models of inflammatory disease, such as complex immune-induced arthritis, 
allergic asthma and diabetes, support an anti-inflammatory role for gal-9 [10-
12]. Unlike gal-1, gal-3 can both positively and negatively regulate the 
inflammatory response, depending on factors such as the specific inflammatory 
conditions or the type of target cell [13].  
Experimental evidence indicates an involvement of Th1 and Th17 
responses in the pathogenesis of psoriasis [14], a chronic inflammatory skin 
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disease affecting 2 to 3% of the human population. Moreover, a recent study 
described a beneficial effect of gal-9 treatment in a model of IL-23–induced, 
psoriasis-like skin inflammation [15]. To examine the potential role of galectins 
in the immunopathogenesis of psoriasis, we analyzed the expression of gal-1, 
gal-3 and gal-9 in psoriasis patients, and related this to the levels of Th1/Th17 
cytokines. We show that expression of gal-1 is decreased both in epidermal 
dendritic cells (DCs) and in peripheral blood myeloid DCs (PBDCs) from these 
patients. Functional assays showed that gal-1 inhibits the Th1 response in co-
cultures of monocyte-derived DCs (moDCs) from psoriasis patients with 
autologous peripheral blood lymphocytes. 
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MATERIAL AND METHODS 
Study subjects and sample collection 
The study was approved by the institutional review board and the independent 
ethics committee of the Hospital Universitario de la Princesa, and conformed to 
the Declaration of Helsinki principles. After giving informed consent, 10 healthy 
individuals and 24 untreated patients with moderate to severe psoriasis were 
enrolled. Patients recruited to the study had a psoriasis area and severity index 
(PASI) ≥ 10 or a body surface area (BSA) ≥10%. The following washout periods 
were established: 14 days for topical corticosteroids, 28 days for conventional 
systemic treatment including corticosteroids, methotrexate, cyclosporin, acitretin 
and phototherapy, and 84 days for biologic anti-TNF agents. Skin punch 
biopsies (10-mm) were obtained from lesional plaque-type psoriatic skin and 
non-lesional skin. Biopsies from non-lesional skin were at least 5 cm from a 
lesional plaque, and were taken preferentially from non sun-exposed areas. In 
some cases 20 ml of venous peripheral blood were obtained. Normal skin and 
peripheral blood samples were obtained from 10 surgical patients without 
cutaneous disease. Data regarding gender, age, duration of psoriasis and 
clinical disease severity (PASI and BSA) are presented in Table 1. 
 
RT-PCR analysis of cytokines and lectins 
Total RNA was isolated using TRIzol reagent (Invitrogen). One microgram of 
RNA was used to generate cDNA. IL-17a, IL-21, IL-23, IL-12b, IL-10, IL-27, gal-
1, gal-3, gal-4, gal-8, gal-9, dectin-1, DCIR and CLEC5A were amplified using 
the Power SYBR green PCR master mix (Applied Biosystems, Warrington UK). 
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mRNA was normalized to GAPDH levels. Primer sequences are shown in Table 
2. 
 
Double immunofluorescence staining and measurement of skin gal-1 
expression 
Skin biopsies were embedded in OCT and frozen. After fixation and 
permeabilization, skin sections were blocked with 100 ug/ml human gamma-
globulin (Sigma-Aldrich, St Louis MO) and 5% FCS in PBS. Sections were 
incubated with anti-gal-1, anti-gal-3 anti-gal7, or anti-gal-9, all at 10 µg/ml for 1 
h and incubated with alexa Fluor 488-DAG. Mouse anti-human CD1a (T6), or 
anti-CD11c. Biotin-coupled mouse anti-human MHC-class II (DCIS 1/21) and rat 
anti-human Alexa-fluor 647-Langerin (Dendritics, Lyon, France) were also used. 
Sections were examined with a Leica DMR immunofluorescence microscopy 
under the same acquisition conditions. Images were analyzed with ImageJ 
(http://imagej.softonic.com) to quantify gal-1 expression. For the analysis of gal-
1 expression, fluorescence intensity was determined in regions of interest 
(ROIs) drawn on CD1a+, Langerin+ or CD11c+, MHC class-II+ cells 
Detailed description of antibodies and other reagents is in supplemental data. 
 
Coculture of moDCs with autologous PBLs. 
MoDCs from psoriasis patients preloaded with SEE (0.1 µg/ml) were co-
cultered with autologous PBLs (1:10) in the presence or absence of h gal-1 (2 
µM) for 5 days. Cells were harvested and intracellular levels of IFN-gamma 
were analyzed in T cells using flow cytometry.  
 
 8 
Flow cytometry and cell sorting. 
To analyze galectin surface expression on primary circulating DCs, PBMCs 
were stained with the following mouse anti-human monoclonal antibodies: 
PerCP-HLA-DR, FITC-CD3, FITC-CD14, FITC-CD16, FITC-CD19, FITC-CD20, 
PE-CD123 and V450-CD11c, and goat polyclonal anti-gal-1, anti-gal-3 or anti-
gal-9 followed by Alexa fluor 647-DAG. Myeloid DCs (mDCs) and plasmacytoid 
DCs (pDCs) were isolated from PBMCs by cell sorting in a FACSAria cell sorter. 
DCs were lysed and galectin expression determined by western blot. 
Epidermal and dermal single-cell suspensions from healthy skin donors were 
obtained after separation of the epidermis and dermis as described [16]. Skin 
cell suspensions were stained with the following antibodies: FITC-HLA-DR and 
PE-anti-CD1a, and anti-gal-1, anti-gal-3 or anti-gal-9 followed by Alexa fluor 
647-DAG for epidermal cells and Pacific blue-CD11c, Pacific orange-CD45, 
FITC-HLA-DR for dermal cells. Dead cells were excluded using 7 ADD.  
 
Statistical analysis. 
Data were analyzed with GraphPad Prism (GraphPad Software Inc, San Diego, 
USA). The Kruskall-Wallis test and Mann-Whittney U-test were used when 
appropriate. Spearman test was used for correlation analysis. Differences were 
considered significant at p<0.05. 
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RESULTS. 
Galectin expression is defective in psoriatic skin 
To explore the potential role of galectins in the immunopathogenesis of 
psoriasis, we conducted an RT-PCR analysis of the expression of gal-1, gal-3, 
gal-4, gal-8 and gal-9 and the lectins DCIR, CLEC5A and dectin-1 in non-
lesional and lesional skin samples from 24 psoriasis patients and control 
samples from 10 healthy subjects. Compared with the skin of healthy subjects, 
lesional and non-lesional skin biopsies from psoriasis patients showed low 
expression of gal-1 mRNA (Fig. 1A, p<0.05). Levels of gal-3 and gal-4 were 
also low in lesional skin, but expression in non-lesional (asymptomatic) samples 
was similar to the level in skin from healthy patients. In contrast, gal-8 and gal-9 
expression was similar in all three types of sample (Fig 1A). Dectin-1 was 
detected at high level in lesional skin, in agreement with a recent report [17]. 
Conversely, we did not observe differences in the expression of CLEC5A and 
DCIR.  
Increasing evidence suggests that effector Th1 and Th17 cells are key players 
in the pathogenesis of psoriasis [18]. In order to validate our skin samples, we 
analyze the mRNA expression of Th1 and Th17 cytokines. RT-PCR analysis 
revealed high expression of IL-17a, IL-21, IL-12b, IL-23 of in lesional skin of 
psoriasis patients compared with both non-lesional skin and skin samples from 
healthy donors (p<0.05 Fig. 1B and supplemental Fig. 1). We found higher IL-
27 mRNA expression in lesional skin of psoriasis patients than in skin samples 
from healthy donors (Supplemental Fig. 1), according to previous data [19]. IL-
27 expression was also above in asymptomatic skin from psoriasis patients, but 
this difference was not statistically significant. In contrast, expression of the anti-
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inflammatory cytokine IL-10 was low in lesional and non-lesional skin from 
psoriasis patients compared with healthy donor skin (p <0.05, Fig. 1B). 
Statistical analysis showed that low levels of gal-1 are associated with high 
levels of IL-17 (p=<0.0001, r2=0,463), and with low levels of IL-10 (p=<0.0001, 
r2=0,393) (Fig. 1C). 
 
Gal-1, gal-3 and gal-9 are expressed in Langerhans cells. 
Dendritic cells are central participants in immune mechanisms, and 
abnormal activation and function of DCs are associated with several chronic 
inflammatory conditions, including psoriasis [20]. Despite the importance of 
galectins in immune response regulation, there has been little study of their role 
in human primary DCs. To study the immune regulatory function of gal-1, gal-3 
and gal-9 in psoriasis, we examined their expression on skin DCs. 
Immunofluorescence analysis of MHC class-II+ cells in skin sections from 
healthy subjects revealed expression of gal-1 and gal-9 in MHC class-II+ 
stellate cells within the epidermis of healthy individuals, pointing to expression 
on Langerhans cells (LCs) (Fig. 2A). Gal-3 and gal-7, a galectin characteristic of 
keratinocytes [21], were highly expressed on epidermal keratinocytes (Fig. 2A). 
The high expression of gal-3 epidermal cells masks the possible expression of 
these galectins on MHC-class II epidermal cells.  In addition we analyze the 
expression of gal-1, gal-3 and gal-9 on LC isolated from epidermal sheets. Flow 
cytometry analysis clearly showed the expression of gal-1, gal-3 and gal-9 on 
LCs (CD1a+ cells gated for HLA-DR expression, Fig. 2B).  
 
Gal-1 expression is reduced in Langerhans cells from psoriasis patients 
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Double-immunofluorescence staining of skin sections from psoriasis patients 
showed weak staining of gal-1 on epidermal CD1a+ cells in comparison with 
healthy donors. To quantify this difference, we measured the mean 
fluorescence intensity of gal-1 staining on CD1a+ epidermal cells in skin 
sections from eight psoriasis patients and eight healthy subjects. (Supplemental 
Fig. 2A). This analysis showed that levels of gal-1 are lower in epidermal 
CD1a+ DCs from lesional and non-lesional skin from psoriasis patients 
compared with healthy donor skin (p<0.05) (Supplemental Fig. 2B). Recently, it 
has been described that a subpopulation of inflammatory dendritic epidermal 
cells (IDECs) are CD1a+ [16].  In order to assess the expression of gal-1 
specifically in LC, three-color immunostaining was performed in skin samples 
(Fig. 3A). The analysis of gal-1 expression showed that Langerhans cells 
(langerin+ CD1a+) from psoriasis patients express low levels of Gal-1 
compared with healthy donors (Fig. 3B). The low levels of gal-1 were also 
corroborated in total lysates of skin biopsies from 2 patients and 2 healthy 
donors by western blot (Fig. 3C).  
 
Gal-1 expression in other populations of skin DCs. 
Due to the lower expression of gal-1 in CD1a+ cells, we analyzed whether there 
was a differential expression between IDEC CD1a+ and Langerhans cells. The 
analysis of gal-1 expression in four-color immunostaining (MHC class-II, CD1a, 
langerin and gal-1) from lesional psoriatic skin revealed that IDECs express 
very low levels of gal-1 (Fig 4A).  
Beside LC, dermal DCs (dDCs) are the other major population of skin DC in 
healthy skin [22]. An additional population of inflammatory dermal DCs 
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(CD11c+) has been recently described in patients with psoriasis [23]. The 
analysis of galectin expression on dDCs by flow cytometry of DCs derived from 
healthy donor skin showed a mild expression of gal-1 and gal-9 (Fig. 4B and 
data not shown). Three-color immunostaining (MHC class-II, CD11c and gal-1) 
of skin samples from psoriasis patients and healthy donors corroborated the low 
expression of gal-1 in dDCs in healthy donors (Fig. 4C) and showed an even 
lower expression in psoriasis patients (Supplemental Fig. 3)  
 
Galectins are differentially expressed in peripheral DC subsets, and gal-1 
expression is defective in peripheral DCs of psoriasis patients 
Like skin, peripheral blood contains distinct DC populations. The main PBDC 
subsets are myeloid DCs (mDCs, CD11c+) and plasmacytoid DCs (pDCs, 
CD123+) [24]. These subsets differ in their origin, surface markers, and 
functions [25]. FACS analysis of galectin expression in PBDCs from healthy 
donors revealed higher surface expression of gal-1, gal-3 and gal-9 on the 
surface of mDCs compared with pDCs (Fig. 5A). In contrast, the 
immunoregulatory molecules ICOS and ICOSL showed no significant 
differences in expression. Higher expression of gal-1 and gal-9 in mDCs was 
also detected by western blot of mDCs and pDCs isolated from peripheral blood 
by cell sorting. We next determined whether galectin expression on peripheral 
blood mDCs was affected in psoriasis. Flow cytometry analysis revealed 
significantly lower gal-1 expression on mDCs from psoriasis patients (Fig. 5B). 
Correlation analysis between disease activity (PASI) and gal-1 expression in 
mDCs showed that higher disease activity indexes are associated with lower 
levels of gal-1 (Fig. 5C; r2=-0.5662, p=0.03). Expression of gal-3 and gal-9 was 
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also slightly lower, but these differences were not statistically significant. Levels 
of ICOS and ICOSL were similar in psoriasis patients and healthy subjects. To 
determine whether the reduced expression of gal-1 was also observed in other 
inflammatory skin condition, gal-1 was analyzed in peripheral mDCs from 
patients with atopic dermatitis. Our results showed that expression of gal-1 in 
mDCs from atopic patients is similar to the expression observed in healthy 
subjects (Fig 5D). 
 
Inhibition of galectin binding increases IFN-gamma production and 
decreases IL-10 production by CD4+ T cells 
Gal-1 and gal-9 have been described as negative regulators of the Th1 immune 
response [3][26]. To assess this, we measured IFN-gamma and IL-10 
production in co-cultures of CD4+ T cells with human moDCs preloaded with 
superantigen staphylococcal enterotoxin E (SEE) in the presence or absence of 
lactose (50mM), an inhibitor of galectin binding. Intracellular staining revealed 
that lactose-mediated inhibition of galectin binding augments IFN-gamma 
production by CD4+ T cells (Fig. 6A). Conversely, lactose inhibited IL-10 
production induced by SEE (Fig. 6A). 
We next probed the ability of gal-1 to regulate IFN-gamma production in 
cells from psoriasis patients. moDCs from psoriasis patients were preloaded 
with SEE and co-cultured autologous PBLs. This analysis showed that 
exogenously added gal-1 inhibited IFN-gamma production by T cells from 
psoriasis patients (Fig. 6B). Western blot of total lysates of moDCs from 
psoriasis patients and healthy donors untreated and treated with LPS showed 
the lower expression of this protein in cells from psoriasis samples (Fig. 6C).  
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DISCUSSION 
In this study we show that Langerhans cells and peripheral mDCs from 
psoriasis patients express low levels of gal-1. In addition, gal-1 is able to reduce 
the IFN-gamma secretion produced by lymphocytes from these patients. 
Current understanding of the exacerbated immune response observed in 
psoriasis and other inflammatory diseases is based mainly on the study of the 
upregulation of pro-inflammatory molecules. Accordingly, several components 
of the pathways involved in T-cell activation are well-established targets in 
psoriasis antibody-based therapies, for example anti-TNF-alpha, anti-LFA-1, 
anti-LFA-3, and more recently anti-IL-12/IL-23 [14, 27]. However, recent studies 
acknowledge the importance of anti-inflammatory signals that counterbalance 
the inflammatory response. Galectins are implicated in the negative regulation 
of the immune response, participating in processes such as immune cell 
proliferation [28], apoptosis [29], cellular adhesion and migration [30-32], and 
modulation of the interactions between T cells and APCs [33].  
This study shows that primary human skin DCs express gal-1, gal-3 and 
gal-9 on their cell surface. Moreover, we detected differential expression of gal-
1 and gal-9 in peripheral blood myeloid and plasmacytoid DCs. Although 
additional studies would be necessary, we could speculate that the differential 
expression of gal-1 and gal-9 might account for different functions in these cells. 
The role of endogenous gal-1 in DCs has recently been studied in a 
mouse model of encephalomyelitis. Galectin-1, either exogenously supplied or 
regulated endogenously, drove the differentiation of DCs toward a regulatory 
function, promoting T cell tolerance [34][15]. Most evidence pointing to gal-1 as 
a negative regulator of the immune response has been gathered in animal 
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models of inflammatory diseases, and studies in human disease are 
comparatively scarce. Here, we demonstrate that psoriasis patients have low 
expression of gal-1 in peripheral blood myeloid DCs and in LCs of lesional and 
non-lesional skin that together with previous studies in animal models [34] 
indicate an important role of gal-1 in the immunopathogenesis of psoriasis. The 
positive role of gal-1 in IL-10 production has been proposed as one of the 
mechanisms involved in the inhibition of Th1 and Th17 responses [34-36]. Our 
results are consistent with this notion and show that blockade of galectin 
binding reduces the levels of IL-10 during antigen presentation. Together with 
the lower expression of IL-10 observed in psoriatic skin, these results indicate 
that defects in gal-1 expression by DCs may promote the Th1 and Th17 
immune response in psoriasis, likely by controlling IL-10 expression.  
The co-culture experiments showed that galectin inhibition increases 
IFN-gamma production by CD4+ T cells in response to antigen presentation by 
DCs, suggesting that galectins also regulate the production of pro-inflammatory 
cytokines. Interestingly, IFN-gamma production was decreased by addition of 
recombinant gal-1 to autologous co-cultures of PBLs with moDCs from psoriasis 
patients. The effects of gal-1 on T cells are likely due to the binding of cell-
surface glycoproteins on these cells. A number of T cell glycoproteins, including 
CD2, CD3, CD7, CD45 and CD43 have been shown to act as receptors for gal-
1 binding and to be involved in gal-1-mediated T cell death [37]. However, the 
absence of apoptosis induction under the doses used in our assays suggests a 
non-apoptotic mechanism and a gal-1 partner on activated T cells not described 
yet. It is known that gal-1 is able to modulate the TNF-alpha and IFN-gamma 
secretion without affect cell viability [38]. The role of galectins in the 
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pathogenesis of psoriasis may also be due to their effect on other cell types. In 
this regard, gal-1 inhibited keratinocyte migration in a model of wound healing 
[39].  
Dendritic cells are important for the induction not only of T-cell immunity, 
but also of tolerance. The maintenance of peripheral tolerance has been 
proposed to involve LC migration to the draining lymph node during steady 
state. However, DC tolerogenicity is not specific to a DC subset or restricted to 
the immature APC state [40]. The means by which DCs convey tolerance are 
not entirely clear, but involve the secretion of suppressive cytokines such as IL-
10 and the induction of regulatory lymphocytes. The expression of specific 
galectin members on LCs and myeloid peripheral blood DCs may play an 
important role in the physiology of these cells. 
Our results are consistent with a model in which galectin-1 expression 
and engagement limit skin inflammatory responses, and suggest that galectin-1 
downregulation in human DCs may contribute to the exacerbation of the 
inflammatory response observed in psoriasis. The increased recognition of 
galectins as immunoregulatory molecules could lead to new therapeutic 
approaches to restoring the immune equilibrium lost in psoriasis. 
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Table 1. Clinical characteristics of psoriasis patients and healthy subjects. 
 Psoriasis patients Healthy 
subjects 
SUBJECTS (n) 24 10 
SEX (M/F) 13/11 4/6 
AGE (years) 49.7 (26-81) 49.1 (44-69) 
PASI 20.76 (9.3-53)  
BSA (%) 23 (10-90)  
TIME OF EVOLUTION (y) 22.5 (8-63)  
Results are expressed as median (interquartile range). M: male; F: female;  
PASI: Psoriasis Area and Severity Index; BSA: Body Surface Area.  
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Table 2. Sequence of primers used for RT-PCR 
Gen Forward Reverse 
GADPH 5’AGCCACATCGCTCAGACAC3’ 5’GCCCAATACGACCAAATCC3’ 
GAL-1 5’AGCGGGAGGCTGTCTTTC3’ 5’CCTGGTCGAAGGTGATGC3’ 
GAL-3 5’GAGCCTACCCTGCCACTG3’ 5’AGGCAAAGGCAGGTTATAAGG3’ 
GAL-4 5’TTTGATCTGTCCATTCGCTG3’ 5’CCTGGATTTCCAATGTGTCC3’ 
GAL-8 5’AGCTTAGGCTGCCATTCG3’ 5’CCTGCTAGTAGGTCAACATTAAAGC3’ 
GAL-9 5’CACACARGCCTTTCCAGA3’ 5’AAGAGGATCCCGTTCACCAT3’ 
IL-10 5’TGGGGGAGAACCTGAAGAC3’ 5’CCTTGCTCTTGTTTTCACAGG3’ 
IL-27 5’GCCAGGAGTGAACCTGTACC3’ 5’TGGTGGAGATGAAGCAGAGA3’ 
IL-17A 5’TGGGAAGACCTCATTGGTGT3’ 5’GGATTTCGTGGGATTGTGAT3’ 
IL-12B 5’CCCTGACATTCTGCGTTCA3’ 5’AGGTCTTGTCCGTGAAGACTCTA3’ 
IL-21 5’AGGAAACCACCTTCCACAAA3’ 5’GAATCACATGAAGGGCATGTT3’ 
IL-23A 5’TGTTCCCCATATCCAGTGTG3’ 5’TCCTTTGCAAGCAGAACTGA3’ 
DECTIN-1 5’CTTTCTCGGCCCCAGACT3’ 5’TTGGGTAGCTGTGGTTCTGA3’ 
DCIR 5’GAGAAGGACTGTGCTAGAATGGA3’ 5’TGCAGATTCTGGAAGATGAAATC3’ 
CLEC5A 5’GGCGTTGGATCAACAACTCT3’ 5’GATCCTGCGGTAGCTGATG3’ 
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FIGURE LEGENDS. 
Fig. 1. Lesional and non-lesional skin from psoriasis patients expresses 
low levels of gal-1 and IL-10. RT-PCR analysis of the indicated lectins (A) and 
cytokines (B) genes in non-lesional and lesional skin samples from psoriasis 
patients and control samples from healthy subjects. Expression levels were 
normalized to GAPDH. Bars represent means ± SEM from 24 lesional (black), 
24 non-lesional (grey) and 10 healthy samples (empty). Differences between 
groups were analyzed by the Kruskall-Wallis and Bonferroni test (* p<0.05 
compared with healthy). C. Correlation analysis of gal-1, IL-17 and IL-10 mRNA 
levels in psoriasis patients. Correlation was tested using Spearman test. Data 
correspond to lesional skin in the case of IL-17 correlation and both lesional and 
non-lesional skin for IL-10. 
 
Fig. 2 Gal-1, gal-3 and gal-9 are expressed in Langerhans cells in normal 
skin. A. Double immunofluorescence analysis of skin from a healthy subject for 
expression of galectins 1, 3, 7 or 9 (green) and MHC-II (red), nuclei were 
counterstained with Hoechst (blue). Arrowheads mark galectin expression on 
LCs. B. Three-color flow cytometry analysis of galectin expression in DCs 
isolated ex vivo from the epidermal sheet of normal skin. Cells were gated for 
HLA-DR expression, and galectin expression was then determined on CD1a+ 
cells.  
 
Fig. 3. Langerhans cells from psoriasis patients express low levels of gal-
1. A. Immunofluorescence analysis of gal-1 expression in skin sections from a 
healthy donor and a psoriasis patient. Triple immunofluorescence of CD1a 
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(red), langerin (magenta) and gal-1 (green) is shown. Arrowheads mark gal-1 
expression on LCs. B. Quantification of gal-1 expression on Langerhans cells. 
Gal-1 signal intensity was measured on CD1a+ langerin+ cells using ImageJ 
softaware. Data are means±SD of fluorescence intensity from four psoriasis 
patients and four healthy controls; at least 50 cells were analyzed for each skin 
section. C. Gal-1 expression in total lysates of skin biopsies from 2 psoriasis 
patients (one of them from lesional and non-lesional skin) and 2 healthy donors. 
Vimentin expression was used as loading control. 
 
Fig 4. Gal-1 expression in IDECs and dermal DCs (dDC). A. Four-color 
immunofluorescence of lesional skin from psoriasis patients. Skin samples were 
immunostained with anti-MCH class-II (red), anti-CD1a (blue), anti-langerin 
(magenta) and anti-gal-1 (green). Gal-1 signal intensity was measured as in Fig. 
3 on MHC class II+ CD1a+ langerin+ cells (LCs) and MHC class-II+ CD1a+ 
langerin – (IDECs). LCs are indicated by solid line and IDECs by dashed line 
regions. B. Flow cytometry analysis of gal-1 expression in dDCs isolated ex vivo 
from the dermal sheet of normal skin. Data inside histogram correspond to 
mean fluorescence intensity (MFI). Three-color immunofluorescence from a 
healthy donor skin biopsy stained with anti-gal-1 (green), anti-MHC class-II (red) 
and anti-CD11c (white) is shown. Regions indicate dDCs. 
 
Fig. 5. Peripheral blood myeloid DCs from psoriasis patients express low 
levels of gal-1.  A. Gal-1, gal-3 and gal-9 are highly expressed in CD11c+ DCs 
compared with CD123+ DCs. PBMCs were obtained from 10 ml samples of 
peripheral blood from healthy donors, and expression of the indicated 
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molecules was evaluated by flow cytometry. Data are means±SEM from 14 
independent experiments. Gal-1 and gal-9 in total lysates from mDCs and pDCs 
isolated from peripheral blood by cell sorting. B. Expression of regulatory 
molecules in mDCs from psoriasis patients and healthy subjects. Protein 
expression was determined in CD11c+DCs by flow cytometry as in A. Bars 
represent means±SEM from 12 psoriasis patients and 14 healthy subjects. C. 
Gal-1 expression in mDCs from healthy subjects (n=14), psoriasis patients 
(n=12), and atopic dermatitis patients (n=6). Differences were analyzed by the 
Mann-Whitney test, * p<0.05. D. Negative correlation of gal-1 expression in 
mDCs and disease activity (PASI) in psoriasis patients. Correlation between 
gal-1 expression and PASI was analysed by Spearman test. 
 
Fig. 6. Gal-1 inhibits IFN-gamma production in psoriasis patients. A. 
Galectin inhibition increases IFN-gamma expression and decreases IL-10 
production. SEE-preloaded moDCs and allogeneic CD4+ T cells both from 
healthy donors, were co-cultured for 5 days in the presence or absence of 
lactose (50 mM), and intracellular levels of IFN-gamma (n=5) and production of 
IL-10 (n=10) were determined by flow cytometry and ELISA, respectively. 
Differences between treatments were analyzed by paired t test. B. Gal-1 
partially inhibits IFN-gamma production by LT from psoriasis patients. SEE-
preloaded moDCs and autologous LT from psoriasis patients were co-cultured 
for 5 days with or without 2 µM gal-1, and intracellular levels of IFN-gamma 
were determined in CD4+ T cells by flow cytometry. Results from five psoriasis 
patients are shown. Differences between treatments were analyzed by the 
Kruskal Wallis test. C. Gal-1 expression in total lysates of moDCs from 1 
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psoriasis patient and 1 healthy donor is shown. moDCs at 7d with or without 
LPS were lysed and loaded on a 12% polyacrylamide gel. 
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Supplemental Fig. 1. Cytokine expression in skin biopsies from psoriasis 
patients and healthy donors by RT-PCR.  mRNA expression of Th1 and Th17 
cytokines in lesional and non-lesional skin samples from psoriasis patients and 
samples from healthy subjects. Expression was normalized to GAPDH. Bars 
represent means±SEM. from 24 lesional, 24 non-lesional and 10 healthy 
samples. Differences between groups were analyzed by the Kruskall-Wallis and 
Bonferroni Test (* p<0.05). 
 
Supplemental Fig. 2.  Epidermal CD1a+ cells from psoriasis patients 
express low levels of gal-1. A. Immunofluorescence analysis of gal-1 
expression in skin sections from a healthy donor and a psoriasis patient. Double 
immunofluorescence of CD1a (red) and gal-1 (green) is shown. Arrowheads 
mark gal-1 expression on CD1a+ cells. B. Quantification of gal-1 expression on 
CD1a+ cells. Gal-1 signal intensity was measured on CD1a+ cells using ImageJ 
softaware. Data are means±SD of fluorescence intensity from four psoriasis 
patients and four healthy controls; at least 50 cells were analyzed for each skin 
section. 
 
Supplemental Fig. 3. Quantification of gal-1 expression on dDCs. Gal-1 
signal intensity was measured on CD11c+ MHC class-II+ cells using ImageJ 
softaware in skin samples from lesions and non-lesions of psoriasis patients 
and healthy subjects. Data are means±SD of fluorescence intensity from four 
psoriasis patients and four healthy controls. 
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